EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Impact of Acid‐Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage

Panli Cardona, Natasha Strydom, Brett Houk

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1489 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Panli Cardona und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Antacids, Beverages, Food-Drug Interactions, Omeprazole. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotorasib exhibits pH‐dependent solubility, making it susceptible to altered exposures when coadministered with acid‐reducing agents (ARAs). Several clinical studies were conducted to investigate the impact of ARAs on sotorasib pharmacokinetics under different clinically relevant scenarios and to identify potential mitigation strategies. Upon coadministration of 960 mg of sotorasib and 40 mg of omeprazole under fasted conditions, sotorasib area under the concentration‐time curve (AUC) and maximum observed plasma concentration (C max ) decreased approximately 42% and 57%, respectively. Following coadministration with 40 mg of famotidine under fed conditions, sotorasib AUC and C max decreased approximately 38% and 35%, respectively. The coadministration of sotorasib and 40 mg of omeprazole under fed conditions led to a 57% and 65% decrease in sotorasib AUC and C max , respectively. When sotorasib was coadministered with omeprazole and an acidic beverage compared to sotorasib alone, AUC and C max decreased approximately 23% and 32%, respectively, leading to a 19.0 percentage‐point increase in AUC and a 24.6 percentage‐point increase in C max for sotorasib when compared to coadministration of sotorasib with omeprazole under fasted conditions. Sotorasib exposure decreased when coadministered with proton pump inhibitors and H 2 receptor antagonists. Coadministration with an acidic beverage increased sotorasib exposure upon concomitant administration with omeprazole, which may represent a clinically attractive method to allow ARA use with sotorasib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntacidsBeveragesFood-Drug InteractionsOmeprazoleTriazolesAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveCross-Over StudiesDrug InteractionsFamotidineFastingHydrogen-Ion ConcentrationProton Pump Inhibitors

Stichwörter der Autor:innen

acid‐reducing agentsdrug‐interactionsotorasib

Substanzen

AntacidsFamotidineOmeprazoleProton Pump InhibitorsTriazoles

Autor:innen und Institutionen

  • Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA.

Zitieren

APA

Cardona, P., Strydom, N., & Houk, B. (2025). Impact of Acid‐Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1489

Vancouver

Cardona P, Strydom N, Houk B. Impact of Acid‐Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1489

BibTeX
@article{Cardona2025,
  author = {Cardona, Panli and Strydom, Natasha and Houk, Brett},
  title = {Impact of Acid‐Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1489}
}
Kostenlos starten →